KOSPIBiotech & Pharma068270

Celltrion

₩208,000▼ 2.35%2026-11-18 close
Market Cap
₩48.3T
Turnover
₩64B
Volume
300K
Shares out.
230M
PER
36.3×
PBR
2.8×
EPS
₩5,857
Dividend Yield
0.35%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩750 per share · Prices as of the 2026-11-18 close

01

Report overview

New Launches Lift Margins; Net Profit Conversion Is the Test

Celltrion's operating margin rose into the low-30s percent in 3Q 2026 on new biosimilar sales, yet attributable net income fell to KRW 75 billion, so how operating gains convert into shareholder profit is the key item to watch.

  1. 1

    Operating profit in 2025 reached KRW 1.17 trillion, up 137.5%, and the operating margin recovered from 13.8% in 2024 to 28.1%.

  2. 2

    Revenue in 3Q 2026 was KRW 1.58 trillion and operating profit KRW 525.3 billion, up 53.1% and 74.3% year on year, respectively.

  3. 3

    Attributable net income in the same quarter fell 79.7% from the prior quarter to KRW 75 billion, moving opposite to operating profit.

  4. 4

    New products rose to 67% of biosimilar sales, with Stoboclo and Osenvelt (KRW 112.2 billion) and Aptozma (KRW 81.1 billion) leading growth.

  5. 5

    Daol Investment & Securities raised its target price to KRW 310,000 on November 17, 2026, and NH Investment & Securities presented KRW 300,000 on October 28, 2026.

02

Business structure

Celltrion develops and manufactures biosimilars, which are copies of biologic medicines, and its core revenue markets are Europe and the United States. In its 3Q 2026 results commentary, the company pointed to direct sales through its local subsidiaries as a growth driver.

By product, Stoboclo and Osenvelt sales reached KRW 112.2 billion in 3Q 2026, up 52.7% from the prior quarter, with wider listing as a preferred drug by US pharmacy benefit managers (PBMs) cited as the reason.

Aptozma sales rose 27.3% to KRW 81.1 billion in the same quarter, with European tender wins and expanded US sales cited as drivers.

The company said Omlyclo recorded a market share above 90% in Spain, and a securities firm noted that after its US launch in October 2026 Omlyclo secured a large healthcare supply contract and PBM preferred-drug listing.

By contrast, Zymfentra sales were KRW 35.6 billion in 3Q 2026, down 23.8% from the prior quarter, so growth speed differs even among new products. According to securities analysts, new products rose from 54% of biosimilar sales in 3Q 2025 to 67% in 3Q 2026.

As a result, higher-margin follow-on products have become a central lever for margin improvement. In competition, industry reports say Celltrion and Samsung Biologics are both expected to reach annual revenue of KRW 5 trillion this year. Segment and regional revenue mix should be checked in the segment disclosures of the business report.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1T₩301.4B29.3%
2025Q4₩1.3T₩475.2B35.7%
2026Q1₩1.1T₩321.9B28.1%
2026Q2₩1.4T₩451.8B32.4%
2026Q3₩1.6T₩525.3B33.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩2.3T₩647.2B₩537.8B28.3%13.0%37.8%
2023₩2.2T₩651.5B₩535.6B29.9%3.2%16.3%
2024₩3.6T₩492B₩422.7B13.8%2.4%19.8%
2025₩4.2T₩1.2T₩1T28.1%6.0%28.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a reported basis, annual revenue fell from KRW 2.28 trillion in 2022 to KRW 2.18 trillion in 2023, down 4.7%, before rising to KRW 3.56 trillion in 2024, up 63.4%, and KRW 4.16 trillion in 2025, up 17.0%.

Operating profit fell 24.5% to KRW 492 billion in 2024, pushing the operating margin down to 13.8%, then recovered to KRW 1.17 trillion in 2025, up 137.5%, with the margin at 28.1%. Among 2022 to 2025, 2025 was the largest year for revenue, operating profit and attributable net income.

Attributable net income reached KRW 1.03 trillion in 2025, up 143.6%, while net income including non-controlling interests was KRW 1.03 trillion in the same year.

Operating cash flow declined from KRW 901.9 billion in 2024 to KRW 646.1 billion in 2025, and the debt-to-equity ratio rose from a low of 16.3% in 2023 to 28.7% in 2025. Total equity at the end of 2025 was KRW 17.4 trillion.

By quarter, 1Q 2026 revenue was KRW 1.14 trillion, down 13.9% from the prior quarter, but operating profit of KRW 321.9 billion exceeded the KRW 300 billion first-quarter target the company set at the start of the year.

Operating profit rose in 2Q 2026 (KRW 451.8 billion) and 3Q 2026 (KRW 525.3 billion), marking two consecutive quarters of growth, and the company attributed the gains to a higher share of high-margin follow-on products, cost structure improvements and production efficiency.

Attributable net income moved in the opposite direction, falling from KRW 528.4 billion in 4Q 2025 to KRW 346.1 billion in 1Q 2026, KRW 370.2 billion in 2Q 2026 and KRW 75 billion in 3Q 2026. Attributable net income for the last four quarters totaled KRW 1.32 trillion.

The non-operating items and tax lines that explain the gap between operating profit and attributable net income should be checked in the notes to the business report.

The preliminary figures announced on October 12, 2026 (revenue KRW 1.5 trillion and operating profit KRW 510 billion, preliminary) differ from the regular report.

05

Industry analysis

Biosimilars enter the market after the patents on originator biologics expire, so pricing pressure and shifts in market share determine results. After operating profit declined in 2024, Celltrion has been in a phase where new-product sales growth and cost improvements since 2025 are lifting profit.

In the US, listing as a preferred drug by PBMs has become the key to prescription growth. In Europe, national tender awards largely determine revenue. The company said Aptozma's European tender wins contributed to sales growth and that Omlyclo secured a Danish national tender award.

In competition, Celltrion is compared with Samsung Biologics, one of the two leading Korean bio companies, and industry reports say both are expected to reach annual revenue of KRW 5 trillion this year.

Securities analysts said exchange-rate volatility remains a variable for earnings, and noted that new-product sales growth offset the effect of exchange rates in 3Q 2026.

NH Investment & Securities estimated Celltrion's EV/EBITDA for next year at about 17 times, not far from a competitor level of 16 times, and argued that its faster growth and profitability warrant a structural premium.

Price cuts and the entry of later biosimilar competitors are industry-wide variables, to be checked through product-level market share trends.

06

Outlook

The company aims to meet its 4Q 2026 and full-year business plan, citing expanded prescriptions for Omlyclo in the US and wider supply in Europe as growth drivers.

In its start-of-year business plan disclosure, the company set quarterly operating profit targets of KRW 300 billion for 1Q, KRW 400 billion for 2Q and at least KRW 500 billion for 3Q, and exceeded each target through 3Q. Securities firms' 2027 estimates differ in scale.

Daol Investment & Securities projected 2027 revenue of KRW 6.90 trillion and operating profit of KRW 2.47 trillion, with the operating margin rising from 32.8% in 2026 to 35.8%.

NH Investment & Securities estimated 2027 revenue of KRW 6.75 trillion and operating profit of KRW 2.44 trillion, while Daishin Securities expected KRW 6.71 trillion and KRW 2.29 trillion. Daol said higher-margin new products such as Omlyclo and Steqeyma would drive profit growth in 2027.

A view also emerged that Omlyclo's entry into Japan could become a new growth driver. Whether rising Zymfentra prescriptions translate into revenue growth was cited by analysts as a task to confirm.

The next checkpoints are the 4Q 2026 preliminary results, the start-of-2027 business plan disclosure, and the 2026 annual business report.

07

Valuation

PER
36.3×
PBR
2.8×
ROE
7.8%
EPS
₩5,857
BPS
₩75,587
Dividend per share
₩750

Attributable net income for the last four quarters totals KRW 1.32 trillion, and the smallest of those quarters is 3Q 2026 at KRW 75 billion. Reading the current share price therefore depends on how quickly the earnings base recovers.

One view accepts a premium over book value, while another takes a cautious stance given earnings volatility. NH Investment & Securities estimated EV/EBITDA for 2027 at about 17 times, not far from a competitor level of 16 times.

IBK Investment & Securities said growth expectations were already reflected at the start of the year, but judged that the valuation multiple could rise if new-product growth is confirmed.

Target prices have moved higher since October 2026: Daol Investment & Securities presented KRW 310,000 on November 17, 2026, while NH Investment & Securities presented KRW 300,000 on October 28, 2026, and Daishin Securities presented KRW 290,000 on the same day.

The key to interpreting the multiple is whether the 2027 operating profit estimates are realized and whether attributable net income keeps pace with operating profit growth.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Rapid growth in new products

Stoboclo and Osenvelt sales reached KRW 112.2 billion in 3Q 2026, up 52.7% from the prior quarter, while Aptozma rose 27.3% to KRW 81.1 billion. New products rose to 67% of biosimilar sales from 54% a year earlier.

The company and securities analysts describe Omlyclo as widening the growth base through supply contracts and listings in Europe and the US.

Structural improvement in operating margin

The operating margin recovered to 28.1% in 2025 from 13.8% in 2024, and operating profit rose for two consecutive quarters to KRW 525.3 billion in 3Q 2026. The company cited a higher mix of high-margin follow-on products and cost structure improvements.

Quarterly operating profit exceeded the targets the company set at the start of the year in each quarter from 1Q to 3Q 2026.

Target price increases and 2027 estimates

Daol Investment & Securities raised its target price from KRW 290,000 to KRW 310,000 on November 17, 2026, and estimated 2027 operating profit at KRW 2.47 trillion. NH Investment & Securities presented a target price of KRW 300,000 on October 28, 2026.

Daishin Securities said it expected 2027 operating profit of KRW 2.29 trillion. Reports said all three cited new-product sales growth as the basis for 2027 profit growth.

09

Bear factors

Sharp drop in attributable net income

Attributable net income in 3Q 2026 fell to KRW 75 billion, down 79.7% from the prior quarter and 77.4% from a year earlier. Operating profit rose in the same quarter to KRW 525.3 billion, so the gap between the two profit lines is the main open question. The non-operating items and tax lines behind this gap are to be checked in the business report notes.

Dependence on new products and uneven product trends

With new products at 67% of biosimilar sales, growth in a handful of products now drives overall results. Zymfentra sales fell 23.8% from the prior quarter to KRW 35.6 billion in 3Q 2026, and analysts flagged whether rising prescriptions translate into revenue as a task. PBM listing decisions in the US also affect the growth pace of individual products.

Valuation resting on estimate assumptions

Securities firms raised target prices on the assumption of higher operating profit in 2027, and one report said a structural premium is needed. If those assumptions fall short, the premise behind the multiple comes under pressure. Exchange-rate volatility also remains a variable in earnings estimates. Even within the trillion-won range of 2027 operating profit estimates, the forecasts differ.

10

Risk factors

Exchange rate

Exchange-rate volatility remains a key variable in earnings estimates. High exchange rates from July were seen as a possible burden on results, while analysts said new-product sales growth offset the effect in 3Q 2026. Because revenue is largely overseas, won-converted profit moves with exchange rates.

Reliance on US PBM listings

Growth in the US depends heavily on whether PBMs list products as preferred drugs. Omlyclo secured supply contracts and listings after its US launch in October 2026, but the pace of prescription growth is a point to check in upcoming quarterly results. Changes in listing terms could also affect sales of products such as Stoboclo and Osenvelt.

Earnings volatility

In 2024, revenue rose 63.4% yet operating profit fell 24.5%, pushing the operating margin down to 13.8%. The margin recovered to 28.1% in 2025, but the profit structure has changed sharply within a single year before. Whether quarterly margin trends have reduced this volatility is the next point to check.

11

What to watch next

  1. December 31, 2026 (fourth-quarter end)

    Whether Omlyclo's US prescriptions and PBM listings expansion show up in fourth-quarter revenue is the point to check. Whether Zymfentra sales rebound is also to be checked in the same period.

  2. Around January to February 2027 (date not fixed)

    This is when the preliminary 4Q 2026 results are expected. The key items are the 4Q operating profit relative to KRW 525.3 billion in 3Q and whether attributable net income follows operating profit.

  3. Early 2027

    Whether the start-of-2027 business plan disclosure sets quarterly operating profit targets is the point to check. The company exceeded its 2026 quarterly targets for three consecutive quarters.

  4. Around late March 2027

    The 2026 annual business report will show confirmed full-year results, the non-operating and tax breakdown, and the reasons for the gap between attributable net income and operating profit.

12

Overall view

Celltrion's 3Q 2026 revenue of KRW 1.58 trillion and operating profit of KRW 525.3 billion were the largest of the disclosed quarters on both measures, with the operating margin rising to 33.3%.

Viewed alongside 2025 full-year operating profit of KRW 1.17 trillion, up 137.5%, the profit structure is clearly different from after the margin decline in 2024. New products rose to 67% of biosimilar sales, and Stoboclo, Osenvelt and Aptozma drove quarterly sales.

On the other side, attributable net income fell to KRW 75 billion in the same quarter, so whether operating profit converts into shareholder profit is the next point to check. Zymfentra's sales decline, exchange-rate volatility and a growth structure that depends on US PBM listings remain negative factors.

Securities firms raised target prices on estimates of 2027 operating profit between KRW 2.29 trillion and KRW 2.47 trillion, but these are assumptions specific to each firm. The next checkpoints are the 4Q 2026 preliminary results, the start-of-2027 business plan disclosure and the 2026 annual business report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. biz.heraldcorp.com
  2. thefairnews.co.kr
  3. huffingtonpost.kr
  4. news.mtn.co.kr
  5. pharmnews.com
  6. ftoday.co.kr
  7. newstnt.com
  8. biztribune.co.kr
  9. todaymild.com
  10. vegannews.co.kr
  11. dev.re.kr
  12. newspim.com
  13. m.news.nate.com
  14. fnnews.com
  15. hankyung.com
  16. news.nate.com
  17. newspim.com
  18. m.thinkpool.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis